Massive diabetes drug showdown: 780,000 patients reveal which pill protects heart and kidneys
NCT ID NCT05220917
First seen Jan 10, 2026 · Last updated May 13, 2026 · Updated 19 times
Summary
This study looks at real-world data from over 780,000 people with type 2 diabetes to compare four common second-line medications: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The goal is to see which ones are safest and most effective at preventing heart attacks, strokes, heart failure, and kidney problems. Researchers are not giving anyone new treatments—they are analyzing existing health records to find the best options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.